Optimize Resource Allocation for Your HEOR Function

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Global Medical Affairs Resourcing Benchmark for HEOR Functions”

STUDY OVERVIEW

As organizations strive to deliver innovative therapies while navigating complex regulatory environments and cost pressures, optimizing resource allocation for the Health Economics and Outcomes Research (HEOR) function becomes paramount. The strategic choice between insourcing and outsourcing HEOR activities holds the potential to augment core capabilities, minimize costs, and provide impactful support across therapeutic areas.

Best Practices, LLC undertook this benchmarking research to probe the resourcing details and capabilities of HEOR groups by assessing the productivity, outsourcing benchmarks, spend, and staffing at mid-sized and large biopharma organizations. The study equips HEOR leadership with strategic acumen to navigate complexities adeptly, boost productivity, and foster sustainable growth within Global Medical Affairs HEOR functions.

KEY TOPICS

HEOR Outsourcing Trends
Scope of Support
Productivity and Outsourced Capabilities
HEOR Staffing Dynamics
Hybrid Resourcing Benefits

KEY METRICS

Alignment of HEOR groups within benchmark companies
Nature of HEOR support across the product lifecycle
Average scope of HEOR support and total annual HEOR spend analysis
Average annual volume of HEOR activities
Outsourced HEOR capabilities
Outsourcing vs. productivity matrix for various HEOR activities
Staffing levels for each HEOR role
Brand-specific staffing
Factors driving outsourcing and insourcing in HEOR

SAMPLE KEY FINDINGS

HEOR Spend: Approximately 73% of HEOR spend is allocated toward outsourcing.

Factors Driving Insourcing in HEOR: 63% of companies say it is “absolutely critical” to retain some degree of in-house HEOR expertise, and many believe insourced research yields higher quality work product.

METHODOLOGY

This study offers tailored benchmarks and insights focused on the HEOR function. The data from this study is drawn by engaging 22 Medical leaders from 20 leading mid-cap and large biopharma organizations, with expertise encompassing HEOR, Medical Publications & Strategy. HEOR insights are meticulously distilled to ensure relevance and applicability within the scope of this study.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Consumer Products; Health Care; Clinical Research; Laboratories

Companies Profiled:
AbbVie; Acadia Pharmaceuticals; Agenus; Alexion Pharmaceuticals; Astellas; Domp�; Fidia Pharma USA Inc.; Gilead Sciences; Novartis; Novo Nordisk; Organon; Pfizer; Pixacore; Protagonist Therapeutics; Regeneron; Sanofi; Sobi; Teva Pharmaceuticals; United Therapeutics; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Global Medical Affairs Resourcing Benchmark for HEOR Functions

ID: 5804

Features:

Pages/Slides: 32

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64603295EA762E97D00258B1D00454BE7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-global-medical-affairs-resourcing-benchmark-for-heor-functions?opendocument
18
19opendocument
203.238.82.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB